Development of FISH panel for Risk Adaptive Approach to Korean multiple myeloma treatment
Not Applicable
Active, not recruiting
- Conditions
- Diseases of the blood and blood -forming organs and certain disorders involving the immune mechanism
- Registration Number
- KCT0002028
- Lead Sponsor
- ational Evidence-based Healthcare Callaborating Agency
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
1) Diagnosed and treated at Seoul National University Hospital for multiple myeloma between 1-Jan-2005 and 31-Dec-2015
2) Korean patients
3) adult patients, defined as those who are 18 years old or older
Exclusion Criteria
1) non-Koreans
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method overall survival ;response to bortezomib;response to thalidomide;progression free survival after hematopoeitic stem cell transplantation (HSCT);response to high dose chemotherapy, conventional